1. Home
  2. ATEN vs PHAT Comparison

ATEN vs PHAT Comparison

Compare ATEN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$20.60

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$11.96

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEN
PHAT
Founded
2004
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
ATEN
PHAT
Price
$20.60
$11.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$22.67
$17.33
AVG Volume (30 Days)
921.6K
928.9K
Earning Date
02-04-2026
03-05-2026
Dividend Yield
1.16%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
$290,557,000.00
$147,190,000.00
Revenue This Year
$9.40
$221.87
Revenue Next Year
$7.65
$80.37
P/E Ratio
$36.32
N/A
Revenue Growth
11.03
460.30
52 Week Low
$13.81
$2.21
52 Week High
$21.90
$18.31

Technical Indicators

Market Signals
Indicator
ATEN
PHAT
Relative Strength Index (RSI) 66.40 38.10
Support Level $20.17 $11.83
Resistance Level $21.31 $13.17
Average True Range (ATR) 0.78 0.74
MACD 0.29 -0.08
Stochastic Oscillator 79.60 21.85

Price Performance

Historical Comparison
ATEN
PHAT

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: